Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ranbaxy In Deeper Trouble As Apotex Seeks Declaratory Judgment On Valtrex, Aricept Exclusivity; Will Nexium and Lipitor Be Next In Line?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - U.S. FDA's punitive actions against Ranbaxy's manufacturing units in India is set to hit the company where it hurts most. Ranbaxy's 180-day exclusivity status for anti-herpes drug Valtrex (valacylovir) is in trouble as Canadian generic drug maker Apotex has sought a declaratory judgment on the drug that "will start the running of Ranbaxy's 180-day exclusivity period, even if Ranbaxy has yet to market its product.

Table

View full table

Tags:
Latest Headlines

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Metagenomi Looks For Upside To Moderna’s Exit

Executives On The Move: Senior Moves At Innovent Biologics, Actym Therapeutics And Enanta Pharmaceuticals

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

See All
UsernamePublicRestriction

Register

SC072417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By